NewsSource: EClinCloud

EClinCloud Interviewed by VCBeat: Winning Over Investors in Just 30 Minutes, Solving Digital Clinical Trial Pain Points from a Medical Perspective, and Competing with Global IT Giants—How Does This New Entrant Do It?

8 min readEClinCloud Editorial Team
EClinCloud exclusive interview with VCBeat: Winning over investors in just 30 minutes, solving digital clinical trial pain points from a medical perspective—how does this new entrant take on international IT giants? Archive article cover

Source: EClinCloud. Author: E-Pharma Manager.

Accelerating timelines, improving efficiency, and reducing costs are the core mission of digital tools. EClinCloud was founded right where industry pain points meet a major industry tailwind. Bringing together seasoned industry experience, this emerging company aims to support the clinical development of new drugs and medical devices with science and medicine as its foundation.


Benefiting from the drug review reforms launched in 2015, innovation in China's pharmaceutical industry has experienced explosive growth. R&D funding has continued to grow, innovative drug pipelines have expanded rapidly, and the number of new drug launches has steadily increased.
In May 2022, an article published in Nature by CDE-affiliated researchers, titled "Trends in innovative drug development in China," conducted a detailed analysis of China's Investigational New Drug (IND) and New Drug Application (NDA) data over the past 10 years (2010–2020). The data showed that both IND and NDA figures achieved rapid growth over that 10-year period.
However, one key metric—"the length of the clinical trial phase"—increased rather than decreased, lengthening from 2572 days to 2688 days. Improving clinical trial efficiency appears to have become one of the most urgent pain points to address in current new drug innovation. This was precisely the industry need identified by EClinCloud founder Qin Long, and his original motivation for starting EClinCloud.

01


Built to Solve Industry Pain Points

As is well known, clinical trials are the most expensive, time-consuming, and critical stage before a new drug reaches the market. Improving the efficiency of clinical drug trials and completing the collection, organization, and verification of clinical trial data in a scientific, accurate, and compliant manner are shared goals across pharmaceutical R&D. "In recent years, although more and more new drugs have been launched, the level of informatization and digitalization across the clinical research process remains low. This keeps R&D costs persistently high, leaves room to improve efficiency, and may also affect clinical data quality downstream," said Qin Long.
In addition, the global outbreak of the COVID-19 pandemic in 2020 made these pain points in clinical research even more pronounced. "For example, traditional offline processes such as patient recruitment, informed consent, outcome follow-up, patient compliance management, and clinical monitoring were heavily affected during the pandemic."
With an understanding of current clinical research pain points and confidence in improving drug R&D efficiency through his accumulated experience, Qin Long transitioned from a professional manager to an entrepreneur in early 2020. Out of this, EClinCloud was founded, positioned to provide an integrated pharmaceutical R&D SaaS platform solution for pharmaceutical and medical device companies, research institutions, CROs, and other stakeholders.
EClinCloud was founded right where industry pain points meet the tailwind of a broader trend.
Qin Long recalled that when the company was first founded, it took less than 30 minutes after meeting with investors to win their backing and secure its first angel round investment. "Investors favored EClinCloud based on three considerations. First, all industries—including the pharmaceutical industry—are looking to reduce costs and improve efficiency through technological innovation and digital solutions; that is the overarching trend. Second, EClinCloud builds its products around industry pain points grounded in scientific and medical understanding, with a clear business model. Third, and perhaps most importantly, our executive team members all have years of industry experience, which adds greater certainty to the company's future development."
Subsequent business practice not only validated the investors' judgment, but also demonstrated the EClinCloud team's ability to solve industry pain points.
A new entrant always begins by solving the "toughest cases."
In 2020, EClinCloud received a clinical outcome assessment (COA) request from a pharmaceutical company: to assess participant outcomes in a neurology clinical trial in a scientific, standardized, and compliant manner. According to Qin Long, the client had approached nearly every digital clinical trial vendor available at the time without finding an effective, feasible solution.
Ultimately, drawing on its accumulated experience and resources and a professional understanding of clinical trial operations, the EClinCloud team helped the client complete the outcome assessment for this clinical trial.
"EClinCloud's advantage is that our core team has an average of over 15 years of industry experience. This gives us a deep understanding that in the digitalization of clinical trials, IT technology is a tool, whereas understanding clinical protocols and clinical operations from a medical and scientific perspective is the true foundation for identifying client needs and solving industry pain points," said Qin Long. In his view, this is also why EClinCloud was able to prevail over international IT giants in bidding for a clinical digitalization project from a large multinational pharmaceutical company (MNC).
According to Qin Long, over the past two years, more than one hundred clinical studies have been completed using EClinCloud's digital systems, of which 70% were drug studies, and the number of repeat customers has also been growing. "Moreover, we even receive projects referred by some of our peers."

02


Achieving three "ones" in two years

Over EClinCloud's two years of operations, what has given Qin Long the greatest sense of accomplishment can be summed up as three "ones": building a team with substantial industry experience and an international outlook; creating an integrated clinical research SaaS platform grounded in customer needs; and serving a group of clients, including leading domestic and multinational (MNC) pharmaceutical companies.
Deep accumulated industry experience and a broad international outlook are defining traits of EClinCloud's executive team.
Founder and Chief Executive Officer Qin Long has over 16 years of experience applying technology in the clinical research industry and previously served as Asia-Pacific head of an international technology company, leading rapid business growth in the region. Chief Technology Officer Wu Weiping has more than 30 years of experience in IT fields including healthcare and previously held C-level leadership roles at major international companies such as Oracle, Hitachi Data Systems, and IBM. Chief Commercial Officer Su Quanyu has over 12 years of experience in clinical research, understands the end-to-end clinical trial process, and consistently adopts the sponsor's perspective to provide tailored solutions for clients. Vice President of Product Zeng Xiaoxia has more than 20 years of experience in software development and technical support for new drug clinical trials, with extensive practical experience in regulatory compliance requirements for clinical trial systems and documentation across major ICH member jurisdictions such as the United States, Europe, and Japan. Notably, EClinCloud's organizational structure also includes a Chief Medical Officer role: "At our company, the head of medicine is also a C-level position, specifically so we can better understand clinical trials from a scientific and medical perspective."
In building its integrated platform, EClinCloud has evolved from individual point solutions to a comprehensive suite, with the goal of achieving data "interconnectivity" across systems.
After two years of system development, EClinCloud has built 5 digital clinical trial systems: eCOA (electronic clinical outcome assessment), CTMS (Clinical Trial Management System), eTMF (electronic Trial Master File management system), EDC (Electronic Data Capture system), and RTSM (Randomization and Trial Supply Management system).
After two years of real-world operation, Qin Long believes the time is ripe to launch the integrated platform.
Recently, the Center for Drug Evaluation (CDE) issued "General Considerations for Involving Patients in Drug Development (Draft for Comment)," and EClinCloud Chief Commercial Officer Su Quanyu was pleased to find that the direction advocated in the guideline aligns closely with EClinCloud's longstanding "patient-centric" approach to building an integrated SaaS cloud platform supporting clinical evidence. "All of EClinCloud's systems are built around a 'patient-centric' approach. Taking the eCOA system as an example, EClinCloud's electronic clinical outcome assessment (eCOA) system has been proven across numerous clinical trials in developed countries and has established a rich library of outcome assessment scale models centered on trial participants across various drug areas—this is EClinCloud's differentiating advantage."
Reportedly, EClinCloud's operation of its eCOA system in the China region is exclusively licensed from the international clinical evidence support company Signant Health. Signant Health is a leading global evidence-generation company whose eCOA solutions have supported nearly 2000 clinical trials across more than 130,000 institutions, covering approximately 960,000 patients.
Accelerating timelines, improving efficiency, and reducing costs are the core mission of digital tools. The goal of clinical trial digitalization is to establish a platform that connects sponsors, research institutions, investigators, and patients, enabling standardized data flows and seamless coordination across clinical trial execution. Data indicate that if digital tools are fully utilized, both clinical trial costs and timelines could potentially be reduced by roughly one-quarter.
Moreover, "clinical trial digitalization improves the scientific rigor, reliability, and objectivity of clinical data collection, which in turn helps support the smooth launch of new drugs," said Su Quanyu.
In fact, even before the COVID-19 pandemic, clinical research stakeholders in some developed countries were already calling for the industry to transition toward a fully interconnected digital trial ecosystem to improve clinical trial efficiency and quality, thereby enabling seamless data exchange and execution. The logic is straightforward: in a fragmented setup, researchers must log into multiple different systems to work, while study sites also have to execute trial processes across multiple systems, which inevitably increases time costs at every stage of a clinical trial.
This was also the unmet customer need in clinical research that Qin Long and his team identified. From the very beginning, Qin Long and his team firmly believed that aggregating data distributed across separate systems in a compliant, standardized manner through advanced IT infrastructure—and then redistributing it back to each system—not only improves efficiency, but also provides more effective tools for the subsequent scientific collection, synthesis, and organization of clinical outcome assessment (COA).
In addition, from a commercial positioning standpoint, Qin Long believes that launching an integrated platform will be a good opportunity for EClinCloud, as a new entrant, to "leapfrog ahead." "Everyone is building an integrated platform or preparing to build one, but for EClinCloud, although it is a new entrant, having no legacy burden actually makes it easier to build an integrated platform."
In mid-July, EClinCloud's integrated clinical research SaaS platform will officially launch; "this takes EClinCloud a step further in its mission to solve clinical pain points."

Article image

(All images and text in this article were provided by the contributor.)

Read the original WeChat article

Related reading

Archived article cover: With Rising Pharmaceutical Submissions and Tightening Investment, How Can Digital Solutions Help Clinical Research Reduce Costs and Improve Efficiency?News7 min readWith Rising Drug Filings and Tightening Investment, How Can Digital Solutions Help Reduce Costs and Improve Efficiency in Clinical Research?As the biopharmaceutical industry continues to develop, innovative drug R&D has entered a period of rapid growth, and the number of clinical drug trials is trending upward. Alongside this, improving clinical trial efficiency and reducing the costs and risks of clinical research have become urgent priorities for a growing number of pharmaceutical companies and research institutions. Using digital tools to advance the digital and intelligent development of clinical trials is undeniably the prevailing trend. To better meet the needs of digital and intelligent clinical development and share the latest achievements and solutions, EClinCloud recently convened in Chengdu its first User Conference, "Digital and Intelligent Empowerment: Symbiosis and Win-Win," bringing together pharmaceutical industry leaders for discussions.Article cover for "Scale scoring: a different score from every rater? An overview of the history of neuropsychological scale assessment"News8 min readInconsistent Scale Scoring? Understanding Neuropsychological Scale AssessmentIn neurology, neuropsychological assessment is an indispensable tool in clinical diagnosis and research. However, during clinical scale assessments, raters may apply varying degrees of subjective judgment and interpret the scales inconsistently, leading to differences in scoring outcomes; if a rater uses leading language or questions during the assessment, this can also introduce bias into the results. In the field of neuropsychology in particular, neuropsychological assessment results often serve as the primary endpoint of clinical trials; biased results may reduce a clinical trial's reliability and, in severe cases, lead to study failure. Therefore, standardized training on the use of neuropsychological assessment scales is necessary to...Archived article cover: EClinCloud eCOA system passes CFDI inspection, supporting marketing approval of Raynovent's COVID-19 treatment leritrelvir tabletsNews4 min readEClinCloud eCOA System Passes CFDI Inspection, Supporting Marketing Approval of Raynovent's COVID-19 Treatment Leritrelvir TabletsOn March 23, 2023, in accordance with the relevant provisions of the Drug Administration Law and under the special drug approval procedures, the National Medical Products Administration (NMPA) granted conditional marketing approval to leritrelvir tablets (brand name: Leruiling), a Category 1 innovative drug submitted by Guangdong Raynovent Biotech Co., Ltd. (hereinafter referred to as "Raynovent"). The drug is an oral small-molecule therapy for novel coronavirus infection, indicated for the treatment of adult patients with mild-to-moderate novel coronavirus infection (COVID-19).